New label expansion for Cimzia in USA

Belgian drugmaker UCB (Euronext Brussels: UCB) has entered the field of immuno-dermatology with the US Food and Drug Administration’s (FDA) approval of a label expansion for the blockbuster inflammatory diseases drug Cimzia (certolizumab pegol).

The regulator has approved the therapy for use in adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy, making the first Fc-free, PEGylated anti-TNF treatment option for this indication.

Alice Gottlieb, professor of dermatology at New York Medical College and lead investigator, said: “Today’s approval provides patients and their healthcare professionals with a robust new biologic option that provides durable disease control.